NantHealth (NASDAQ: NH) is one of 20 publicly-traded companies in the “Medical Software & Technology Services” industry, but how does it compare to its competitors? We will compare NantHealth to similar businesses based on the strength of its analyst recommendations, dividends, risk, institutional ownership, earnings, profitability and valuation.

Valuation & Earnings

This table compares NantHealth and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
NantHealth $100.38 million -$184.10 million -1.72
NantHealth Competitors $413.57 million -$24.55 million 397.35

NantHealth’s competitors have higher revenue and earnings than NantHealth. NantHealth is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings for NantHealth and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NantHealth 0 0 4 0 3.00
NantHealth Competitors 86 434 825 13 2.56

NantHealth currently has a consensus price target of $9.00, indicating a potential upside of 194.12%. As a group, “Medical Software & Technology Services” companies have a potential upside of 19.95%. Given NantHealth’s stronger consensus rating and higher possible upside, analysts clearly believe NantHealth is more favorable than its competitors.

Insider and Institutional Ownership

7.1% of NantHealth shares are held by institutional investors. Comparatively, 62.9% of shares of all “Medical Software & Technology Services” companies are held by institutional investors. 58.0% of NantHealth shares are held by insiders. Comparatively, 24.5% of shares of all “Medical Software & Technology Services” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


This table compares NantHealth and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NantHealth -225.76% -46.09% -25.23%
NantHealth Competitors -14.57% -7.27% 0.22%

Volatility and Risk

NantHealth has a beta of -1.51, suggesting that its share price is 251% less volatile than the S&P 500. Comparatively, NantHealth’s competitors have a beta of 1.02, suggesting that their average share price is 2% more volatile than the S&P 500.


NantHealth competitors beat NantHealth on 8 of the 12 factors compared.

About NantHealth

NantHealth, Inc. is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples. The Company also offers Nant Operating System (NantOS) and NantOS applications to healthcare providers and payors, self-insured employers and biopharmaceutical companies. It offers CLINICS, an integrated solution that includes GPS Cancer, NantOS and the NantOS applications. The CLINICS solution includes System Infrastructure, Knowledge Platform, Provider Platform and Payor Platform.

Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with's FREE daily email newsletter.